Common Side Effects of Wainua
Wainua (eqlontrifamab-bcmm), approved by the FDA in 2024 for polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, most often causes injection-site reactions like redness, pain, or swelling, affecting over 20% of patients in trials. Other frequent effects include fatigue, nausea, diarrhea, and urinary tract infections.[1][2]
Serious Side Effects and Warnings
Serious risks include hypersensitivity reactions such as anaphylaxis, angioedema, or cytokine release syndrome (CRS), which occurred in 1-5% of trial participants and can happen after the first dose. Infusion-related reactions are also common, with symptoms like fever, chills, or hypotension. The drug carries a boxed warning for these risks, and patients need monitoring during and after infusions. Eye problems, including vitreous floaters and blurred vision, were reported in up to 10% of cases, potentially linked to underlying amyloidosis.[1][2][3]
Side Effects by Frequency in Clinical Trials
- Very common (≥10%): Peripheral edema, injection-site reactions.
- Common (1-10%): Upper respiratory infections, headache, dizziness, constipation, falls.
- Less common but serious: Liver enzyme elevations, atrial fibrillation worsening, and rare cases of severe infections or bleeding.[2][3]
Trials like HELIOS-B showed higher rates of these in treated patients versus placebo, with 75% experiencing any adverse event.[2]
How Long Do Side Effects Last?
Most injection-site reactions and mild symptoms resolve within days. Hypersensitivity or CRS may require treatment interruption and can recur. Long-term data is limited as Wainua is new; post-marketing reports could reveal more.[1][3]
Who Gets Side Effects and Risk Factors?
Elderly patients or those with heart involvement in hATTR amyloidosis face higher risks of cardiac events or falls. Pre-medication with antihistamines or steroids reduces infusion reactions. No specific contraindications beyond active hypersensitivity.[1][2]
Managing Side Effects
Doctors recommend starting with slower infusions, dose delays, or permanent discontinuation for severe cases. Report eye symptoms immediately, as they may signal disease progression.[3]
[1]: FDA Prescribing Information for Wainua (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761309s000lbl.pdf)
[2]: NEJM HELIOS-B Trial (https://www.nejm.org/doi/full/10.1056/NEJMoa2312380)
[3]: Alnylam Pharmaceuticals Wainua Safety Overview (https://www.wainua.com/)